A Multiple Dose Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of ABT-652 Administered Once Daily in Subjects With an Excessive Daytime Sleepiness Disorder.

Trial Profile

A Multiple Dose Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of ABT-652 Administered Once Daily in Subjects With an Excessive Daytime Sleepiness Disorder.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2011

At a glance

  • Drugs ABT 652 (Primary)
  • Indications Hypersomnia; Narcolepsy
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Apr 2011 Planned End Date changed from 1 Mar 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.
    • 24 Jan 2011 Planned End Date changed 1 Dec 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top